|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online August 24, 2006
doi: 10.1242/10.1242/jcs.03086
Research Article |
B
complexes requires 14-3-3 proteins
Centre Oncologia Molecular, IDIBELL-Institut de Recerca Oncologica, Gran Via km 2.7, Hospitalet, Barcelona 08907, Spain
* Authors for correspondence (e-mail: abigas{at}iro.es; llespinosa{at}iro.es)
Accepted 6 June 2006
 |
Summary |
|---|
 Top Summary IntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
B are responsible for maintaining p65 in the cytoplasm under non-stimulating conditions and promoting the active export of p65 from the nucleus following NFB activation to terminate the signal. We now show that 14-3-3 proteins regulate the NFB signaling pathway by physically interacting with p65 and IB
proteins. We identify two functional 14-3-3 binding domains in the p65 protein involving residues 38-44 and 278-283, and map the interaction region of IB in residues 60-65. Mutation of these 14-3-3 binding domains in p65 or IB results in a predominantly nuclear distribution of both proteins. TNF treatment promotes recruitment of 14-3-3 and IB to NFB-dependent promoters and enhances the binding of 14-3-3 to p65. Disrupting 14-3-3 activity by transfection with a dominant-negative 14-3-3 leads to the accumulation of nuclear p65-IB complexes and the constitutive association of p65 with the chromatin. In this situation, NFB-dependent genes become unresponsive to TNF stimulation. Together our results indicate that 14-3-3 proteins facilitate the nuclear export of IB-p65 complexes and are required for the appropriate regulation of NFB signaling.
Key words: NFB, IB, 14-3-3, Nuclear export, TNF
|
Introduction |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
B activity has been linked to several human diseases such as inflammation and cancer. Several extracellular stimuli such as TNF lead to IB phosphorylation (residues 32-36 in IB) and degradation, thus releasing NFB and permitting the transcriptional activation of NFB target genes. In general, IB proteins inhibit NFB by maintaining p65 in the cytoplasm (reviewed by Baldwin, 1996
) whereas IB plays a unique role in actively removing p65 from the nucleus because of its ability for nucleocytoplasmic shuttling both under basal conditions (Huang et al., 2000; Johnson et al., 1999) or in response to stimuli (Huang et al., 2000; Huang and Miyamoto, 2001; Johnson et al., 1999; Nomura et al., 2003; Tam and Sen, 2001). Cytoplasmic retention of p65 has been classically associated with IB; however, in cells lacking isoforms , ß and 
, p65 is still in the cytoplasm (Tergaonkar et al., 2005). Although p100 and p105 can interact with p65, other unknown proteins may be involved (Moorthy and Ghosh, 2003; Prigent et al., 2000; Tergaonkar et al., 2005).
14-3-3 is a highly conserved family of proteins that regulate a wide variety of signal transduction pathways (Fu et al., 2000; Tzivion et al., 2001) by promoting the cytoplasmic export of prephosphorylated substrates (Brunet et al., 2002; Grozinger and Schreiber, 2000). Many different 14-3-3 targets have already been identified, such as Raf-1 (Thorson et al., 1998), the cell cycle regulator Cdc25 (Lopez-Girona et al., 1999), histone deacetylases (Grozinger and Schreiber, 2000), the proapoptotic factors FKHRL1 (Brunet et al., 2002), Bad (Hsu et al., 1997) and Bax (Nomura et al., 2003), the tumor suppressor p53 (Waterman et al., 1998) or the kinase Par1 (Benton et al., 2002), and most, but not all, require prephosphorylated 14-3-3 binding domains corresponding to the RxxpSxP or RxxxpSxP consensus, where pS represents a phosphorylated serine. Although 14-3-3 are primarily cytoplasmic proteins, it has been shown that protein kinase B-dependent phosphorylation of the 14-3-3 binding sites of FKHRL1, which promote its cytoplasmic translocation, occurs in the nucleus, thus suggesting that the interaction between both proteins takes place in this cellular compartment (Brunet et al., 2002).
Since nucleocytoplasmic shuttling is crucial in the regulation of NFB activity, we investigated whether 14-3-3 proteins may play a role in this signaling pathway. Here we show that 14-3-3 proteins interact with both p65 and IB, and play a role in the regulation of the NFB pathway after TNF treatment by facilitating the export of IB-p65 complexes.
|
Results |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
induces p65 binding to 14-3-3
in response to TNF stimulation and that this interaction was maintained after 60 minutes of chronic treatment in HEK-293T cells (Fig. 1a). We next confirmed this interaction by precipitating endogenous p65 from these cells and detecting 14-3-3 after TNF treatment in the precipitates (Fig. 1b). By sequence analysis, we identified three putative 14-3-3 binding domains containing the RxxSxP and RxxxSxP (Yaffe, 2002), involving residues 38-44 (BD42), 278-283 (BD281), and 336-342 (BD340) of human p65. Nevertheless, only two of these domains, 38-44 and 278-283 are evolutionary conserved, suggestive of their functional relevance (Fig. 1c).
|
In many identified 14-3-3 substrates, phosphorylation is required for 14-3-3 binding (Muslin et al., 1996). To further investigate whether binding of p65 to 14-3-3 was phosphorylation dependent, we incubated protein extracts from TNF-treated HEK-293T cells with acid phosphatase and performed pull-down assays with GST-14-3-3. In Fig. 2a, we show that phosphatase treatment completely abolished the TNF-induced binding of p65 to 14-3-3, indicating that this interaction was phosphorylation dependent. To investigate which kinases were involved in regulating this interaction, we treated HEK-293T cells with different kinase inhibitors such as BAY11-7082 (IKK), JNK inhibitor, SB203580 (p38), wortmannin (PKC and PI3K), PD98059 (ERK) and H89 (PKA and MSK) and used the different cell lysates for pull-down assays with GST-14-3-3 (Fig. 2b and supplementary material, Fig. S1). Our results demonstrated that BAY11-7082 specifically abrogated the interaction between p65 with 14-3-3 suggesting that IKK activity is required for p65 binding to 14-3-3.
|
. With this aim we generated GST fusion proteins that contained these domains from wild-type p65 (GST-BD42, -BD281 and -BD340) and the corresponding Ser to Ala mutants. Wild-type (wt) or mutated GST-p65 peptides were incubated with untreated or TNF-treated cell lysates in the presence of [32P]ATP. We detected TNF-dependent phosphorylation in GST-BD42 and GST-BD281 proteins that was abrogated by the point mutations S42A and S281A (Fig. 2c), whereas GST-BD340 was not phosphorylated. To confirm that S42 and S281 were phosphorylated in response to TNF, an antibody that specifically binds to phosphorylated 14-3-3 binding motifs (-P-14-3-3BM) efficiently recognized precipitated GFP-p65 from TNF treated cells and in a minor extent the GFP-p65 mutants S42A and S281A (Fig. 2d).
To test whether these binding domains were functionally involved in the interaction between p65 and 14-3-3, we performed pull-down assays with cell extracts from HEK-293T cells transfected with GFP-p65wt or the point mutants S42A, S281A and S340A. In Fig. 2e, we show that 30 minutes after TNF treatment, interaction between 14-3-3 and p65 is severely reduced in mutants S42A and S281A. Together, these results indicate that both Ser42 and Ser281 are phosphorylated in response to TNF to create two functional 14-3-3 binding sites in p65. Although we did not detect phosphorylation of Ser340 in response to TNF, we observed a decrease in the interaction between S340A mutant and 14-3-3. Based on this result, we cannot exclude the fact that BD340 is also involved in 14-3-3 binding.
IB interacts with 14-3-3 in a TNF-independent manner
We next tested whether other NFB family members were also associated with 14-3-3 proteins. Using pull-down experiments, we demonstrated that the NFB inhibitor IB binds to GST-14-3-3 in untreated HEK-293T cells, whereas TNF resulted in a decrease in the total levels of IB as expected, and also in the amount of IB bound to 14-3-3 (Fig. 3a). However, co-precipitation experiments from HEK-293T cells transfected with the non-degradable IB32-36 demonstrated that TNF treatment does not inhibit the binding of IB to 14-3-3 (Fig. 3b).
|
B was not required for its binding to 14-3-3 (Fig. 3c). Next, we analyzed the IB protein sequence for the presence of conserved 14-3-3 binding motifs. As we could not identify any consensus, we generated sequential IB deletion mutants (Fig. 3d-f) and tested their ability to bind 14-3-3 in pull-down assays. From these experiments, we identified a unique region in the first ankyrin repeat of IB that was required for the interaction of IB with 14-3-3. Since IB
55-59 still bound GST-14-3-3 whereas IB55-65 did not (Fig. 3f), we propose that 14-3-3 binding domain of IB includes residues AA60-65, that greatly resembles a 14-3-3 binding motif (Fig. 3f).
14-3-3 binding domains of p65 and IB are required for their efficient nuclear export
Since 14-3-3 proteins regulate the subcellular distribution of many of their substrates, we determined the subcellular localization of GFP-p65wt compared with GFP-p65 mutants S42A and S281A in RPW1 (Fig. 4a) and HEK-293T (data not shown) cells. As shown in Fig. 4a, transiently transfected GFP-p65 was mainly cytoplasmic, as expected. Single mutation of S42 or S340 to Ala resulted in a moderate increase in the nuclear localization of GFP-p65 (56% and 66% respectively) compared with the wild type (43%) whereas S281A mutation was sufficient to promote the nuclear retention of p65 in almost all the cells (94%) (Fig. 4a). These results indicate that the 14-3-3 binding domains of p65, and particularly BD281, are required for cytoplasmic localization.
|
B, we determined the subcellular distribution of the 14-3-3-binding-deficient mutant, IB55-65, as well as its capacity to induce cytoplasmic localization of p65 in IB-deficient MEFs. As shown in Fig. 4b, transfected flag-p65 primarily localized in the nucleus in most of the IB-/- cells (86%). Coexpression of the non-degradable IB32-36 or the IB55-59 mutant that binds 14-3-3 leads to the cytoplasmic redistribution of GFP-p65 compared to the control (24% and 19% nuclear, respectively). By contrast, the IB55-65 mutant, lacking the 14-3-3 binding site, failed to retain p65 in the cytoplasm (76% nuclear) (Fig. 4b). Of note, localization of this IB55-65 mutant, containing an intact NES (see Fig. 3f), was predominantly nuclear, suggesting that 14-3-3 also regulates subcellular distribution of IB. As a control, we performed coprecipitation experiments to demonstrate that mutations in the 14-3-3 binding motifs do not affect the interaction between p65 and IB (Fig. 4c,d).
14-3-3 activity is required for the appropriate nuclear export of p65-IB complexes
To test whether the aberrant nuclear distribution of the p65 and IB mutants was due to 14-3-3, we analyzed the subcellular localization of endogenous p65 (Fig. 5a) in control HEK-293T cells transfected with a dominant-negative form of 14-3-3 (DN-14-3-3) (Thorson et al., 1998) that blocks the interaction between p65 and 14-3-3 induced by TNF (Fig. 5b). Confocal microscopy showed that in unstimulated HEK-293T cells, DN-14-3-3 induces a partial redistribution of p65 into the nuclear compartment compared with the exclusively cytoplasmic p65 observed in the control or in cells transfected with wild-type 14-3-3. After 15 minutes of TNF treatment, nuclear entry of p65 was observed in both control cells and cells expressing myc-14-3-3 constructs, as expected. Interestingly, expression of DN-14-3-3 significantly reduced the nuclear export of p65 after 60 minutes of TNF treatment (Fig. 5a). By western blot (Fig. 5a) and immunofluorescence (data not shown) analysis with anti-myc antibody, we confirmed that 80-90% of the cells expressed similar levels of the 14-3-3 constructs. Since IB is mainly responsible for p65 nuclear export after TNF activation, we reasoned that nuclear persistence of p65 in the DN-14-3-3-expressing cells in both non-stimulated and 60-minute TNF-treated cells might be due to (1) the nuclear accumulation of IB-p65 complexes or (2) the impairment of nuclear p65 to bind IB. To investigate these possibilities we isolated nuclear extracts from HEK-293T cells expressing DN-14-3-3, precipitated endogenous p65 and checked for the presence of IB in the precipitates. We demonstrated that nuclear extracts from DN-14-3-3 expressing cells contained increased levels of p65 bound to IB compared with almost undetectable levels of this complex in untransfected cells (Fig. 5c), suggesting that 14-3-3 activity is required for the efficient nuclear export of IB-p65 complexes.
|
We did not detect TNF-dependent interaction of p65 with GST-14-3-3 in IB knockout cells (Fig. 5d), further evidence that a ternary complex is formed after TNF treatment.
To confirm the requirement of 14-3-3 for regulating subcellular distribution of p65, we used specific siRNA to knockdown different 14-3-3 isoforms in HEK-293T cells. As shown in Fig. 5e, treatment with siRNA against both 14-3-3ß and 14-3-3
resulted in the nuclear retention of endogenous p65 compared with HEK-293T control cells and cells treated with the specific 14-3-3 siRNA. Altogether, these results demonstrated that abrogation of specific 14-3-3 activities results in a general redistribution of p65 protein to the nucleus in unstimulated cells and, more interestingly, in response to TNF activation.
14-3-3 proteins are recruited to the chromatin and modulate NFB-dependent transcription
Since 14-3-3 can enter the nucleus to bind specific partners (Brunet et al., 2002; Miska et al., 2001; Wakui et al., 1997) and because after TNF treatment p65 is mainly nuclear, we tested whether the subcellular distribution of 14-3-3 proteins was modulated by TNF. Immunodetection of endogenous 14-3-3 with an antibody recognizing different isoforms demonstrated that 30 minutes of TNF treatment induces a partial redistribution of these proteins from a predominantly cytoplasmic localization into a combined cytoplasmic plus nuclear pattern (Fig. 6a). Nuclear entry of 14-3-3 was confirmed by western blot analysis with nuclear extracts from HEK-293T cells treated with TNF at different time points (Fig. 6b). Our results demonstrated that nuclear levels of 14-3-3 gradually increased following TNF treatment and reached a maximum at 30 minutes. Interestingly, nuclear accumulation of 14-3-3 seemed delayed compared with p65 nuclear entry and both nuclear p65 and 14-3-3 levels decreased after 60 minutes of chronic TNF treatment.
|
Recruitment of 14-3-3 proteins to the chromatin has been shown to occur in both cIAP-2 and IL-8 promoters in response to laminin attachment resulting in the release of chromatin-associated SMRT and facilitating gene activation (Hoberg et al., 2004). We speculated that 14-3-3 could also interact with the chromatin to facilitate the release of chromatin-bound p65 from specific genes, thus participating in the termination of TNF signaling. Chromatin precipitation from NIH-3T3 cells demonstrated that 14-3-3ß, 14-3-3 and IB associated with the IL6, TNF-induced protein 3 (TNFAIP3 or A20) and chemokine (C-C motif) ligand 5 (CCL5 or RANTES) promoters in response to TNF with slightly delayed kinetics compared with p65 recruitment (Fig. 6c). By contrast, in HEK-293T cells transfected with DN-14-3-3, p65 was constitutively associated with the NFB-target promoters in the absence or presence of TNF (Fig. 6d), suggesting that 14-3-3 proteins play a role in regulating the specific interaction of p65 with the chromatin. To test whether 14-3-3 proteins modulate the transcriptional activity of NFB, we performed semiquantitative RT-PCR of different NFB targets from HEK-293T cells transfected with DN-14-3-3. We detected increased basal transcriptional activity from TNFAIP3 (A20) and CCL5 (RANTES) genes, which correlated with the greater association of p65 with the chromatin in unstimulated conditions (Fig. 6d). However, DN-14-3-3-expressing cells became unresponsive to TNF-dependent transcriptional activation (Fig. 6e).
Altogether, our results fit in a model in which 14-3-3 cooperate with IB in the release of p65 from the chromatin of specific promoters and participate in the subsequent nuclear export of IB-p65 complexes after TNF treatment.
|
Discussion |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
). In this study, we show that 14-3-3 proteins bind to both p65 and IB, facilitate the nuclear export of IB-p65 complexes and are required for the appropriate regulation of NFB activity.
Part of the complexity of NFB resides in the regulation of its nucleocytoplasmic shuttling. Although it is clearly established that IB is mainly responsible for sequestering NFB in the cytoplasm, it also participates in the nuclear export of NFB complexes not only after TNF stimulation, but also in basal conditions to ensure NFB-target gene silencing (Huang and Miyamoto, 2001). Nevertheless, it has been recently reported that in the absence of the three classical IB family members, p65 remains localized in the cytoplasm (Tergaonkar et al., 2005). Although p100 and p105 are overexpressed and interact with p65 in these cells, other proteins such as 14-3-3 could also play a role (Moorthy and Ghosh, 2003; Prigent et al., 2000; Tergaonkar et al., 2005). We have characterized two functional 14-3-3 binding consensus sequences including residues 38-44 and 278-283 in p65 that are highly conserved from Drosophila to human.
We also demonstrate that IB interacts with 14-3-3 independently of TNF stimulation. By pull-down assay we characterize a unique functional 14-3-3 binding site in the IB protein involving residues 60-65, close to its nuclear export signal (NES). Interestingly, it has been proposed that 14-3-3 might facilitate subcellular redistribution by masking or unmasking the nuclear localization signal (NLS) or NES of their substrates (Muslin and Xing, 2000). By comparative sequence analysis we show that S63, located in the core of this 14-3-3 binding domain, is exclusively found in the human IB protein but not in closely related species such as mouse or pig, consistent with the finding that phosphorylation is not required for IB to bind 14-3-3.
Although many efforts have been made to identify proteins that interact with the NFB pathway after TNF treatment, direct association between p65 and IB with 14-3-3 has not previously been detected (Bouwmeester et al., 2004).
It has been proposed that formation of heterodimers between different 14-3-3 isoforms could allow interaction between signaling proteins that do not directly associate (Jones et al., 1995). Although this is not the case for p65 and IB, our results suggest that after TNF treatment, phosphorylated nuclear p65 binds to IB and 14-3-3, leading to the formation of a ternary complex that is more efficiently exported from the nucleus. Involvement of 14-3-3 proteins in the export of nuclear factors has been extensively reported, mainly associated with cell differentiation, cell cycle and apoptosis (Brunet et al., 2002; Lopez-Girona et al., 1999; Yoshida et al., 2005), and both altered expression of 14-3-3 and aberrant activation of NFB have been directly implicated in cancer development (reviewed by Garg and Aggarwal, 2002; Hermeking, 2003). More specifically, 14-3-3
is considered a tumor suppressor gene in breast carcinomas by promoting the nuclear export of cdc25 thus leading to cell cycle arrest (Urano et al., 2002). However abrogation of NFB activity is sufficient to inhibit cell proliferation and to induce cell death in MCF-7 and MDA-MB-231 breast cancer cells (Tanaka et al., 2006). Considering our results, it is tempting to speculate that aberrant NFB activation may result from deficiency of 14-3-3 in breast cancer. To address this question we are currently investigating the precise role of specific 14-3-3 isoforms in regulating the NFB pathway in cancer cells.
In summary, we have demonstrated that 14-3-3 proteins are required for regulating the appropriate subcellular distribution of p65 and that abrogation of 14-3-3 activity by DN-14-3-3 or specific siRNAs induces the accumulation of p65-IB complexes in the nucleus and the constitutive binding of p65 to the chromatin. Since efficient nuclear export of p65-IB complexes is required for reestablishing the permissive conditions for NFB to be rapidly activated in response to specific stimuli (Arenzana-Seisdedos et al., 1997; Huang and Miyamoto, 2001), abrogation of 14-3-3 function results in a deficiency in NFB target gene activation after TNF treatment.
|
Materials and Methods |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
B32-36 (Ser32 and Ser36 to Ala mutations), GFP-p65, Flag-p65, myc-14-3-3, myc-14-3-3R56A-R60A (DN-14-3-3), and GST-14-3-3 have been previously described (DiDonato et al., 1995; Thorson et al., 1998). IB and p65 constructs were obtained by PCR and primer sequences are available upon request. PCR products were cloned in-frame into the pGEX-5.3 vector (Pharmacia) or into the pcDNA3.1-HA. GFP-p65 mutants were generated with the QuickChange Site-Directed Mutagenesis Kit (Stratagene). All construct sequences were confirmed by automated sequencing.
Antibodies and inhibitors
Antibodies recognizing IB (sc-1643 and sc-371G), p65 (sc-109), HDAC1 (sc-7872), 14-3-3ß (sc-629) and 14-3-3 (sc-731) were purchased from Santa Cruz Biotechnology. Anti-14-3-3ß antibody (recognizing different 14-3-3 isoforms and referred as -pan-14-3-3) (KAM-CCO13) was from Bioreagents, anti-flag (clone M2) and anti--tubulin antibodies were from Sigma, anti-HA from Babco and anti-HDAC4 (07-040) and anti-IB (06-494) antibodies were from Upstate and anti-phospho-14-3-3 binding motif (9601) was from Cell Signaling. Secondary antibodies conjugated to horseradish peroxidase (HRP) were purchased from DAKO. Fluorescein-conjugated goat anti-mouse or Cy3-conjugated goat anti-rabbit antibodies were from Amersham and Alexa Fluor 594-conjugated goat anti-mouse antibody was from Molecular Probes.
BAY 11-7082, JNK inhibitor II and SB203580 were used at 100 µM, 20 µM and 12 µM, respectively, and purchased from Calbiochem. TNF was purchased from Preprotech and used at 40 ng/ml.
Cell culture and transfection
HEK-293T, RWP1 pancreatic cancer cells, NIH-3T3 murine embryonic fibroblasts (MEF), p65-/- MEF and IB-/- MEFs were cultured in DMEM with 10% FBS. Cells were plated at subconfluence and transfected with calcium phosphate or Lipofectamine Reagent (Invitrogen). Cells were harvested after 24 hours for immunofluorescence, coimmunoprecipitation, ChIP or western blot analysis.
Cell fractionation
Trypsinized cells were incubated in 500 µl of 0.1% NP-40/PBS for 5 minutes on ice and the reaction was stopped by adding 3 ml of cold PBS. Nuclei were isolated by centrifugation at 2,000 rpm and washed with 3 ml of cold PBS twice. After washing, nuclei were lysed for 30 minutes in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 5 mM EGTA, 5 mM EDTA, 20 mM NaF and complete protease inhibitor cocktail (Roche).
siRNA transfection
siRNAs against 14-3-3ß (sc-29186), 14-3-3 (sc-29582), 14-3-3 (sc-29588) or control siRNA (sc-36869) were transfected in HEK-293T cells with the siRNA reagents from Santa Cruz Biotechnology, according to the manufacturer's instructions (sc-36868).
Pull-down assays
Pull-down assays have been previously described (Espinosa et al., 2003). Briefly, GST fusion proteins were purified and incubated with 400 µg of cell lysates for 2 hours at 4°C in lysis buffer and extensively washed. Pulled down proteins were analyzed by western blot.
Coimmunoprecipitation assays
Cells were lysed for 30 minutes at 4°C in 500 µl of PBS containing 0.5% Triton X-100, 1 mM EDTA, 100 µM sodium orthovanadate, 0.25 mM PMSF and complete protease inhibitor cocktail (Roche). After centrifugation, supernatants were incubated for 3 hours at 4°C with 1 µg of the indicated antibody coupled to Protein A-Sepharose beads. Beads were extensively washed with the precipitation buffer and samples were assayed by western blot.
Immunofluorescence
Cells were grown on glass slides and transfected with the indicated plasmids. After 48 hours, cells were fixed in 3% paraformaldehyde and permeabilized with 0.3% Triton X-100, 10% FBS and 5% non-fat dry milk in PBS. After incubation with the appropriate antibodies, slides were mounted with Vectashield plus DAPI or propidium iodide (PI) (Vector) and staining was visualized in an Olympus BX-60 microscope or a Leica TCS-NT laser-scanning confocal microscope equipped with a 63x Leitz Plan-Apo objective (NA 1.4). Representative images were edited using Adobe Photoshop. For each experiment a minimum of 200 cells was counted in the Olympus BX-60 by two independent researchers.
Protein kinase assays
Cells were lysed for 30 minutes at 4°C in 500 ml PBS containing 0.5% Triton X-100, 1 mM EDTA, 100 mM sodium orthovanadate, 0.25 mM PMSF and complete protease inhibitor cocktail (Roche). Cell lysates were assayed for kinase activity on GST-p65 peptides in the presence of [-32P]ATP.
Chromatin immunoprecipitation assay
Chromatin from crosslinked cells was sonicated, incubated overnight with the indicated antibodies in RIPA buffer and precipitated with protein G/A-Sepharose. Crosslinkage of the co-precipitated DNA-protein complexes was reversed, and DNA was used as a template for semiquantitative PCR. Primer sequences are available upon request.
RT-PCR
Total RNA from HEK-293T cells was isolated using Trizol Reagent (Invitrogen), and cDNA was obtained with RT-First Strand cDNA Synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Densitometric analysis of the PCRs was performed with the Quantity One software from Biorad. Oligonucleotide sequences can be provided upon request.
|
Acknowledgments |
|---|
B MEFs and Serveis Cientifico-Tècnics, UB-Bellvitge for confocal microscopy technical support. We thank Veronica Barceló for technical assistance, Claudia Orelio and the members of the lab for helpful discussions. L.E. is an investigator from the Carlos III program. C.A. is a recipient of a MEyC pre-doctoral fellowship (BES-2002-0028), V.F.M. is a recipient of a DURSI pre-doctoral fellowship (2005FI00458). This work was supported by ISCIII/02/3027 and PI041890 grants from Instituto de Salud Carlos III, and from the Fundació La Marató TV3 (Grant 030730). |
Footnotes |
|---|
|
References |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R. T., Virelizier, J. L. and Dargemont, C. (1997). Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J. Cell Sci. 110, 369-378.[Abstract]
Baldwin, A. S., Jr (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649-683.[CrossRef][Medline]
Benton, R., Palacios, I. M. and St Johnston, D. (2002). Drosophila 14-3-3/PAR-5 is an essential mediator of PAR-1 function in axis formation. Dev. Cell 3, 659-671.[CrossRef][Medline]
Bouwmeester, T., Bauch, A., Ruffner, H., Angrand, P. O., Bergamini, G., Croughton, K., Cruciat, C., Eberhard, D., Gagneur, J., Ghidelli, S. et al. (2004). A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat. Cell Biol. 6, 97-105.[CrossRef][Medline]
Brunet, A., Kanai, F., Stehn, J., Xu, J., Sarbassova, D., Frangioni, J. V., Dalal, S. N., DeCaprio, J. A., Greenberg, M. E. and Yaffe, M. B. (2002). 14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J. Cell Biol. 156, 817-828.
DiDonato, J. A., Mercurio, F. and Karin, M. (1995). Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol. Cell. Biol. 15, 1302-1311.[Abstract]
Espinosa, L., Ingles-Esteve, J., Aguilera, C. and Bigas, A. (2003). Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem. 278, 32227-32235.
Fu, H., Subramanian, R. R. and Masters, S. C. (2000). 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647.[CrossRef][Medline]
Garg, A. and Aggarwal, B. B. (2002). Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16, 1053-1068.[CrossRef][Medline]
Grozinger, C. M. and Schreiber, S. L. (2000). Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl. Acad. Sci. USA 97, 7835-7840.
Hermeking, H. (2003). The 14-3-3 cancer connection. Nat. Rev. Cancer 3, 931-943.[CrossRef][Medline]
Hoberg, J. E., Yeung, F. and Mayo, M. W. (2004). SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol. Cell 16, 245-255.[CrossRef][Medline]
Hsu, S. Y., Kaipia, A., Zhu, L. and Hsueh, A. J. (1997). Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11. Mol. Endocrinol. 11, 1858-1867.
Huang, T. T. and Miyamoto, S. (2001). Postrepression activation of NF-kappaB requires the amino-terminal nuclear export signal specific to IkappaBalpha. Mol. Cell. Biol. 21, 4737-4747.
Huang, T. T., Kudo, N., Yoshida, M. and Miyamoto, S. (2000). A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc. Natl. Acad. Sci. USA 97, 1014-1019.
Johnson, C., Van Antwerp, D. and Hope, T. J. (1999). An N-terminal nuclear export signal is required for the nucleocytoplasmic shuttling of IkappaBalpha. EMBO J. 18, 6682-6693.[CrossRef][Medline]
Jones, D. H., Ley, S. and Aitken, A. (1995). Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: implications for function as adapter proteins. FEBS Lett. 368, 55-58.[CrossRef][Medline]
Lopez-Girona, A., Furnari, B., Mondesert, O. and Russell, P. (1999). Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397, 172-175.[CrossRef][Medline]
Miska, E. A., Langley, E., Wolf, D., Karlsson, C., Pines, J. and Kouzarides, T. (2001). Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res. 29, 3439-3447.
Moorthy, A. K. and Ghosh, G. (2003). p105.Ikappa Bgamma and prototypical Ikappa Bs use a similar mechanism to bind but a different mechanism to regulate the subcellular localization of NF-kappa B. J. Biol. Chem. 278, 556-566.
Muslin, A. J. and Xing, H. (2000). 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell. Signal. 12, 703-709.[CrossRef][Medline]
Muslin, A. J., Tanner, J. W., Allen, P. M. and Shaw, A. S. (1996). Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897.[CrossRef][Medline]
Nomura, M., Shimizu, S., Sugiyama, T., Narita, M., Ito, T., Matsuda, H. and Tsujimoto, Y. (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J. Biol. Chem. 278, 2058-2065.
Prigent, M., Barlat, I., Langen, H. and Dargemont, C. (2000). IkappaBalpha and IkappaBalpha/NF-kappa B complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2. J. Biol. Chem. 275, 36441-36449.
Tam, W. F. and Sen, R. (2001). IkappaB family members function by different mechanisms. J. Biol. Chem. 276, 7701-7704.
Tanaka, A., Muto, S., Konno, M., Itai, A. and Matsuda, H. (2006). A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 66, 419-426.
Tergaonkar, V., Correa, R. G., Ikawa, M. and Verma, I. M. (2005). Distinct roles of IkappaB proteins in regulating constitutive NF-kappaB activity. Nat. Cell Biol. 7, 921-923.[CrossRef][Medline]
Thorson, J. A., Yu, L. W., Hsu, A. L., Shih, N. Y., Graves, P. R., Tanner, J. W., Allen, P. M., Piwnica-Worms, H. and Shaw, A. S. (1998). 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol. Cell. Biol. 18, 5229-5238.
Tzivion, G., Shen, Y. H. and Zhu, J. (2001). 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene 20, 6331-6338.[CrossRef][Medline]
Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y. and Inoue, S. (2002). Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417, 871-875.[CrossRef][Medline]
Wakui, H., Wright, A. P., Gustafsson, J. and Zilliacus, J. (1997). Interaction of the ligand-activated glucocorticoid receptor with the 14-3-3 eta protein. J. Biol. Chem. 272, 8153-8156.
Waterman, M. J., Stavridi, E. S., Waterman, J. L. and Halazonetis, T. D. (1998). ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19, 175-178.[CrossRef][Medline]
Yaffe, M. B. (2002). How do 14-3-3 proteins work? - gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett. 513, 53-57.[CrossRef][Medline]
Yoshida, K., Yamaguchi, T., Natsume, T., Kufe, D. and Miki, Y. (2005). JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat. Cell Biol. 7, 278-285.[CrossRef][Medline]
Related articles in JCS:
B - capped by 14-3-3
This article has been cited by other articles:
|
|
 |
|
  J. L. Williams, P. Ji, N. Ouyang, X. Liu, and B. Rigas NO-donating aspirin inhibits the activation of NF-{kappa}B in human cancer cell lines and Min mice Carcinogenesis, February 1, 2008; 29(2): 390 - 397. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
) or transfected with DN-14-3-3 (
) treated with TNF